Abstract
In article number 2003558 by Hongze Liao, Houwen Lin, Yourong Duan, and co‐workers, first class of APP/DR6 inhibitor, polymer–peptidomimetic PEG‐tAHP‐DRI, are developed by utilizing three rationaldesigned screening strategies, which demonstrate promising anti‐hematogenous metastatic activity by inhibiting the binding of amyloid precursor protein (APP) and death receptor 6 (DR6) as well as blocking the necroptosis of vascular endothelial cells induced by tumors cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
